-transparent.png){kind=logo}
The PET imaging properties of three phenyltropane drugs with differing affinities and selectivities for the dopamine over serotonin transporter, were compared. METHODS Carbon-11-CFT (WIN 35,428, 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane), 11C-CCT (RTI-131, 2 beta-carbomethoxy-3 beta-(4-monochlorophenyl)tropane), and 11C-CDCT (dichloropane, 2 beta-carbomethoxy-3 beta-(3,4-dichlorophenyl)tropane) were evaluated as imaging probes for dopamine neurons in five normal and in two MPTP-treated cynomolgus monkeys (macaca fascicularis) using a high-resolution PET imaging system (PCR-I). RESULTS For 11C-CFT, the specific binding ratio (as defined by the ratio of radioactivity levels in striatum versus cerebellum) was 4.2 +/- 0.8 in caudate and 4.9 +/- 1.2 in putamen at 60 min and 4.9 +/- 1.2 and 5.5 +/- 1.1 at 90 min in control animals. In MPTP-treated monkeys the corresponding ratios were 1.4 +/- 0.1 in caudate and 1.5 +/- 0.1 in putamen at 60 min and 1.3 +/- 0.1 in caudate and 1.4 +/- 0.3 in putamen at 90 min. For the monochloro analog of CFT, 11C-CCT, the ratios in control caudate and putamen were 2.7 +/- 0.4 and 3.4 +/- 0.3, respectively, at 60 min and 3.7 +/- 0.5 and 4.4 +/- 0.6, respectively, at 90 min. In MPTP-treated animals, corresponding ratios were 1.4 +/- 0.4 and 1.5 +/- 0.3 at 60 min and 1.4 +/- 0.4 and 1.6 +/- 0.4 at 90 min. The dichloro analog of CFT, CDCT, which has the highest affinity for the dopamine transporter, generated the lowest ratios in control brains, 2.3 +/- 0.4 in caudate and 2.4 +/- 0.5 in putamen at 60 min. In one MPTP-treated monkey, the corresponding ratios were 1.6 +/- 0.4 and 1.8 +/- 0.3. In comparison with 11C-CFT, both 11C-CCT and 11C-CDCT were less selective and had high uptake in the thalamus. CONCLUSIONS The present results clearly indicate that 11C-CFT is a useful ligand for monitoring dopamine neuronal degeneration.
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
January 2019,
Neuroscience letters,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
January 1998,
Methods in enzymology,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
March 1998,
Annals of neurology,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
January 2013,
Journal of labelled compounds & radiopharmaceuticals,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
April 1997,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
September 2006,
Physical review letters,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
March 2019,
Chemical communications (Cambridge, England),
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
January 2015,
Current topics in medicinal chemistry,
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
June 2009,
Methods (San Diego, Calif.),
A L Brownell, and
D R Elmaleh, and
P C Meltzer, and
T M Shoup, and
G L Brownell, and
A J Fischman, and
B K Madras
July 2011,
Seminars in nuclear medicine,
